EP Patent

EP2338473A1 — Pharmaceutical dosage forms of tizanidine and administration routes thereof

Assigned to MDM SpA · Expires 2011-06-29 · 15y expired

What this patent protects

Pharmaceutical composition in liquid dosage form which contains tizanidine hydrocloride aquous solution suitable for the parenteral, intranasal and oral route administration, is described.

USPTO Abstract

Pharmaceutical composition in liquid dosage form which contains tizanidine hydrocloride aquous solution suitable for the parenteral, intranasal and oral route administration, is described.

Drugs covered by this patent

Patent Metadata

Patent number
EP2338473A1
Jurisdiction
EP
Classification
—
Expires
2011-06-29
Drug substance claim
No
Drug product claim
No
Assignee
MDM SpA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.